Neuropathic Pain

Drug Pipeline Analysis and Market Forecasts to 2015

Product Code GDA00765
Publication Date December 2009
Publisher GlobalData
Product Type Report
Pages 60
ISBN Number not applicable
Change currency
PDF £1,265.00 €1,523 $2,000 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Neuropathic Pain

Drug Pipeline Analysis and Market Forecasts to 2015

Neuropathic Pain Drug Pipeline Analysis and Market Forecasts to 2015

Summary

GlobalData, the industry analysis specialist's new report, ""Neuropathic Pain - Drug Pipeline Analysis and Market Forecasts to 2015"" is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

  • Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.
  • Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global neuropathic pain market landscape? - Identify, understand and capitalize.

Contents

  • 1 Neuropathic Pain Market: Executive Summary
    • 1.1 The Neuropathic Pain Market is Forecast to Show Modest Growth until 2015
    • 1.2 Competition in the Neuropathic Pain Market is Strong
    • 1.3 Current Treatment Options are Moderately Successful in Meeting the Market Demand
    • 1.4 Newer therapies in Pipeline are Expected to Increase the Competition
  • 2 Table Of Contents
    • 2.1 List of Tables
    • 2.2 List of Figures
  • 3 Global Neuropathic Pain Market: Market Characterization
    • 3.1 Overview
    • 3.2 Neuropathic Pain Market Size
    • 3.3 Neuropathic Pain Market Forecast and CAGR
    • 3.4 Drivers and Barriers for Neuropathic Pain Market
      • 3.4.1 Drivers for Neuropathic Pain Market
      • 3.4.2 Barriers for Neuropathic Pain Market
    • 3.5 Opportunity and Unmet Need
    • 3.6 Key Takeaway
  • 4 Global Neuropathic Pain Market: Competitive Assessment
    • 4.1 Overview
    • 4.2 Strategic Competitor Assessment
    • 4.3 Product Profile for the Major Marketed Products in the Neuropathic Pain Market
      • 4.3.1 Lyrica (pregabalin)
        • 4.3.1.1 Overview
        • 4.3.1.2 Efficacy
        • 4.3.1.3 Safety
        • 4.3.1.4 Pricing
        • 4.3.1.5 Clinical Study Details
      • 4.3.2 Cymbalta (duloxetine)
        • 4.3.2.1 Overview
        • 4.3.2.2 Efficacy
        • 4.3.2.3 Safety
        • 4.3.2.4 Pricing
        • 4.3.2.5 Clinical Study Details
      • 4.3.3 Lidoderm (lidocaine patch 5%)
        • 4.3.3.1 Overview
        • 4.3.3.2 Efficacy
        • 4.3.3.3 Safety
        • 4.3.3.4 Pricing
        • 4.3.3.5 Clinical Study Details
      • 4.3.4 Neurontin (gabapentin)
        • 4.3.4.1 Overview
        • 4.3.4.2 Efficacy
        • 4.3.4.3 Safety
        • 4.3.4.4 Pricing
        • 4.3.4.5 Clinical Study Details
    • 4.4 Key Takeaway
  • 5 Global Neuropathic Pain Market: Pipeline Assessment
    • 5.1 Overview
    • 5.2 Strategic Pipeline Assessment
      • 5.2.1 Technology Trends Analytic Framework
    • 5.3 Neuropathic Pain Therapeutics - Promising Drugs under Clinical Development
    • 5.4 Molecule Profile for Promising Drugs under Clinical Development
      • 5.4.1 Vimpat (lacosamide)
        • 5.4.1.1 Overview
        • 5.4.1.2 Efficacy
        • 5.4.1.3 Safety
        • 5.4.1.4 Clinical Study Details
      • 5.4.2 Qutenza (capsaicin 8%)
        • 5.4.2.1 Overview
        • 5.4.2.2 Efficacy
        • 5.4.2.3 Safety
        • 5.4.2.4 Clinical Study Details
      • 5.4.3 Fentora
        • 5.4.3.1 Overview
        • 5.4.3.2 Efficacy
        • 5.4.3.3 Safety
        • 5.4.3.4 Clinical Study Details
      • 5.4.4 Ralfinamide
        • 5.4.4.1 Overview
        • 5.4.4.2 Efficacy
        • 5.4.4.3 Safety
        • 5.4.4.4 Clinical Study Details
      • 5.4.5 NP-1
        • 5.4.5.1 Overview
        • 5.4.5.2 Efficacy
        • 5.4.5.3 Safety
        • 5.4.5.4 Clinical Study Details
      • 5.4.6 Sativex
        • 5.4.6.1 Overview
        • 5.4.6.2 Efficacy
        • 5.4.6.3 Safety
        • 5.4.6.4 Clinical Study Details
    • 5.5 Neuropathic Pain Therapeutics Market - Clinical Pipeline by Mechanism of Action
    • 5.6 Neuropathic Pain Pipeline - Pipeline by Clinical Phases of Development
      • 5.6.1 Neuropathic Pain Therapeutics - Regulatory Filing and Phase III Clinical Pipeline
      • 5.6.2 Neuropathic Pain Therapeutics - Phase II Clinical Pipeline
      • 5.6.3 Neuropathic Pain Therapeutics - Phase I Clinical Pipeline
      • 5.6.4 Neuropathic Pain Therapeutics - Preclinical Pipeline
      • 5.6.5 Neuropathic Pain Therapeutics - Discovery Pipeline
    • 5.7 Discontinued / Suspended Drugs for Neuropathic Pain
    • 5.8 Key Takeaway
  • 6 Global Neuropathic Pain Market: Implications for Future Market Competition
  • 7 Global Neuropathic Pain Market: Future Players in Neuropathic Pain Market
    • 7.1 Introduction
    • 7.2 NeurogesX
      • 7.2.1 Overview
      • 7.2.2 Pain Portfolio
        • 7.2.2.1 Marketed Products
        • 7.2.2.2 Pipeline Products
      • 7.2.3 Neuropathic Pain Product Portfolio
        • 7.2.3.1 Qutenza
        • 7.2.3.2 NGX-1998
    • 7.3 Cephalon Inc.
      • 7.3.1 Overview
      • 7.3.2 Pain Portfolio
        • 7.3.2.1 Marketed Products
        • 7.3.2.2 Pipeline Products
      • 7.3.3 Neuropathic Pain Product Portfolio
        • 7.3.3.1 Fentora
    • 7.4 UCB S.A.
      • 7.4.1 Overview
      • 7.4.2 Pain Portfolio
        • 7.4.2.1 Marketed Products
        • 7.4.2.2 Pipeline Products
      • 7.4.3 Neuropathic Pain Portfolio
        • 7.4.3.1 Vimpat
    • 7.5 Newron Pharmaceuticals
      • 7.5.1 Overview
      • 7.5.2 Pain Portfolio
        • 7.5.2.1 Marketed Products
        • 7.5.2.2 Pipeline Products
      • 7.5.3 Neuropathic Pain Product Portfolio
        • 7.5.3.1 Ralfinamide
        • 7.5.3.2 HF0229
    • 7.6 EpiCept Corporation
      • 7.6.1 Overview
      • 7.6.2 Pain Portfolio
        • 7.6.2.1 Marketed Products
        • 7.6.2.2 Pipeline Products
      • 7.6.3 Neuropathic Pain Product Portfolio
        • 7.6.3.1 NP-1
    • 7.7 GW Pharmaceuticals
      • 7.7.1 Overview
      • 7.7.2 Pain Portfolio
        • 7.7.2.1 Marketed Products
        • 7.7.2.2 Pipeline Products
      • 7.7.3 Neuropathic Pain Product Portfolio
        • 7.7.3.1 Sativex
    • 7.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      • 7.8.1 Overview
      • 7.8.2 Pain Portfolio
        • 7.8.2.1 Marketed Products
        • 7.8.2.2 Pipeline Products
      • 7.8.3 Neuropathic Pain Product Portfolio
        • 7.8.3.1 Tapentadol ER
        • 7.8.3.2 JNJ-4216044
        • 7.8.3.3 RWJ-333369 (carisbamate)
    • 7.9 Avanir Pharmaceuticals
      • 7.9.1 Overview
      • 7.9.2 Pain Portfolio
        • 7.9.2.1 Marketed Products
        • 7.9.2.2 Pipeline Products
      • 7.9.3 Neuropathic Pain Product Portfolio
        • 7.9.3.1 Zenvia
    • 7.10 GlaxoSmithKline Plc.
      • 7.10.1 Overview
      • 7.10.2 Pain Portfolio
        • 7.10.2.1 Marketed Products
        • 7.10.2.2 Pipeline Products
      • 7.10.3 Neuropathic Pain Product Portfolio
        • 7.10.3.1 GSK681323
        • 7.10.3.2 Solzira (1838262)
        • 7.10.3.3 GW856553
    • 7.11 AstraZeneca
      • 7.11.1 Overview
      • 7.11.2 Pain Portfolio
        • 7.11.2.1 Marketed Products
        • 7.11.2.2 Pipeline Products
      • 7.11.3 Neuropathic Pain Product Portfolio
        • 7.11.3.1 AZD2066
        • 7.11.3.2 AZD2516
        • 7.11.3.3 AZD6088
        • 7.11.3.4 AZD2423
  • 8 Global Neuropathic Pain Market: Appendix
    • 8.1 Definitions
    • 8.2 Acronyms
    • 8.3 Research Methodology
      • 8.3.1 Coverage
      • 8.3.2 Secondary Research
      • 8.3.3 Forecasting
        • 8.3.3.1 Epidemiology-based Forecasting
      • 8.3.4 Primary Research
      • 8.3.5 Expert Panel Validation
    • 8.4 Contact Us
    • 8.5 Disclaimer
    • 8.6 Sources
  • List of Tables
    • Table 1: Global Neuropathic Pain Therapeutics Market, Revenue Forecasts ($m), 2006-2015
    • Table 2: Major Marketed Products Comparison in the Neuropathic Pain Market, 2009
    • Table 3: Neuropathic Pain Therapeutics - Most Promising Drugs under Clinical Development, 2009
    • Table 4: Neuropathic Pain Therapeutics - Regulatory Filing and Phase III Clinical Pipeline, 2009
    • Table 5: Neuropathic Pain Therapeutics - Phase II Clinical Pipeline, 2009
    • Table 6: Neuropathic Pain Therapeutics - Phase I Clinical Pipeline, 2009
    • Table 7: Neuropathic Pain Therapeutics - Preclinical Pipeline, 2009
    • Table 8: Neuropathic Pain Therapeutics - Discovery Pipeline , 2009
    • Table 9: List of Discontinued Drugs for Neuropathic Pain, 2009
    • Table 10: NeurogesX - Pain Marketed Products, 2009
    • Table 11: NeurogesX - Pain Pipeline Products, 2009
    • Table 12: Cephalon Inc. - Pain Marketed Products, 2009
    • Table 13: Cephalon Inc. - Pain Pipeline Products, 2009
    • Table 14: UCB S.A. - Pain Pipeline Products, 2009
    • Table 15: Newron Pharmaceuticals - Pain Pipeline Products, 2009
    • Table 16: EpiCept Corporation - Pain Pipeline Products, 2009
    • Table 17: GW Pharmaceuticals - Pain Marketed Products, 2009
    • Table 18: GW Pharmaceuticals - Pain Pipeline Products, 2009
    • Table 19: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. - Pain Marketed Products, 2009
    • Table 20: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. - Pain Pipeline Products, 2009
    • Table 21: Avanir Pharmaceuticals - Pain Pipeline Products, 2009
    • Table 22: GlaxoSmithKline plc. - Pain Pipeline Products, 2009
    • Table 23: AstraZeneca - Pain Pipeline Products, 2009
  • List of Figures
    • Figure 1: Global Neuropathic Pain Market Forecast 2006-2015
    • Figure 2: Opportunity and Unmet Need in the Neuropathic Pain Market, 2009
    • Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2009
    • Figure 4: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline, 2009
    • Figure 5: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline - Description, 2009
    • Figure 6: Neuropathic Pain Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2009
    • Figure 7: Neuropathic Pain Pipeline by Phase of Clinical Development, 2009
    • Figure 8: Implications for Future Market Competition in the Neuropathic Pain Market, 2009
    • Figure 9: Neuropathic Pain Therapeutics Market - Clinical Pipeline by Company, 2009
    • Figure 10: GlobalData Methodology
    • Figure 11: GlobalData Market Forecasting Model